Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial
Anne Hege Aamodt, Member Board of Directors at European Stroke Organisation, shared on LinkedIn:
”Published today in The New England Journal of Medicine: the TenCRAOS trial.
We asked a difficult but important question: can early intravenous thrombolysis with tenecteplase improve vision after acute central retinal artery occlusion?
In this randomized phase 3 trial, the answer was no — and treatment was associated with serious safety concerns.
Negative trials matter.
TenCRAOS provides much-needed high-level evidence in a field where treatment decisions are often made under great uncertainty.
These results should inform clinical practice and future guidelines.
Deeply grateful to our multidisciplinary teams in neurology and ophthalmology for an inspiring collaboration, and to all investigators, supporters, and funders — and especially to the patients who generously participated.”
Read the full article here.
Article: A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
Authors: Stephen J. Ryan; Øystein Kalsnes Jørstad; Mona Skjelland; Maiju Pesonen; Claus Z. Simonsen; Toke Bek; Rolf Ankerlund Blauenfeldt, Anne Hege Aamodt et al., for the TenCRAOS Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 31, 2026, 06:18Manuel Requena: Cherrypicking Inclusion in Clinical Trials May Underestimate The Effect of An Intervention
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist